SPTLC2
Serine palmitoyltransferase 2
Also known as: hLCB2a, KIAA0526, LCB2, LCB2A, SPTC2_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- O15270
- Gene
- SPTLC2
- Ensembl
- ENSG00000100596
- Chromosome
- 14
- Canonical length
- 562 aa
- Protein class
- Disease related genes, Enzymes, Human disease related genes, Metabolic proteins, Plasma proteins, Potential drug targets, Predicted membrane proteins
- Subcellular location
- Plasma membrane,Cell Junctions
OverviewNCBI Gene
This gene encodes a long chain base subunit of serine palmitoyltransferase. Serine palmitoyltransferase, which consists of two different subunits, is the key enzyme in sphingolipid biosynthesis. It catalyzes the pyridoxal-5-prime-phosphate-dependent condensation of L-serine and palmitoyl-CoA to 3-oxosphinganine. Mutations in this gene were identified in patients with hereditary sensory neuropathy type I. [provided by RefSeq, Mar 2011]
Canonical amino-acid sequenceUniProt
562 residues, UniProt reviewed canonical sequence.
>O15270|SPTLC2
1 MRPEPGGCCC RRTVRANGCV ANGEVRNGYV RSSAAAAAAA AAGQIHHVTQ NGGLYKRPFN
61 EAFEETPMLV AVLTYVGYGV LTLFGYLRDF LRYWRIEKCH HATEREEQKD FVSLYQDFEN
121 FYTRNLYMRI RDNWNRPICS VPGARVDIME RQSHDYNWSF KYTGNIIKGV INMGSYNYLG
181 FARNTGSCQE AAAKVLEEYG AGVCSTRQEI GNLDKHEELE ELVARFLGVE AAMAYGMGFA
241 TNSMNIPALV GKGCLILSDE LNHASLVLGA RLSGATIRIF KHNNMQSLEK LLKDAIVYGQ
301 PRTRRPWKKI LILVEGIYSM EGSIVRLPEV IALKKKYKAY LYLDEAHSIG ALGPTGRGVV
361 EYFGLDPEDV DVMMGTFTKS FGASGGYIGG KKELIDYLRT HSHSAVYATS LSPPVVEQII
421 TSMKCIMGQD GTSLGKECVQ QLAENTRYFR RRLKEMGFII YGNEDSPVVP LMLYMPAKIG
481 AFGREMLKRN IGVVVVGFPA TPIIESRARF CLSAAHTKEI LDTALKEIDE VGDLLQLKYS
541 RHRLVPLLDR PFDETTYEET EDLocalizationUniProt · AlphaFold · HPA
Whether an antibody against SPTLC2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Other membrane
- Secreted
- No
- Transmembrane segments
- 1
- Mean surface accessibility (rSASA)
- 0.29
- Highest tissue expression
- 30 nTPM
Expression across tissuesHPA
Tissue
- bone marrow: 30 nTPM
- esophagus: 20 nTPM
- stomach: 17 nTPM
- placenta: 17 nTPM
- adipose tissue: 16 nTPM
- colon: 15 nTPM
Single-cell type
- neutrophils: 1,179 nCPM
- tuft cells: 830 nCPM
- neutrophil progenitors: 656 nCPM
- monocyte progenitors: 566 nCPM
- esophageal apical cells: 494 nCPM
- monocytes: 380 nCPM
Immune cell
- non-classical monocyte: 32 nTPM
- classical monocyte: 31 nTPM
- myeloid DC: 31 nTPM
- eosinophil: 27 nTPM
- intermediate monocyte: 24 nTPM
- neutrophil: 19 nTPM
Brain region
- white matter: 98 nTPM
- medulla oblongata: 62 nTPM
- spinal cord: 50 nTPM
- basal ganglia: 50 nTPM
- pons: 50 nTPM
- cerebellum: 49 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about SPTLC2.
Disease | AllUniProt
Conditions SPTLC2 is implicated in, by any mechanism.
- Neuropathy, hereditary sensory and autonomic, 1C (HSAN1C) MIM:613640
Disease | GeneticClinVar
10 pathogenic / likely-pathogenic of 700 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- Neuropathy, hereditary sensory and autonomic, type 1C
- NEUROPATHY, HEREDITARY SENSORY AND AUTONOMIC, TYPE IC, SEVERE
- Inborn genetic diseases
- Hereditary neuropathy or pain disorder
- Charcot-Marie-Tooth disease
Disease | ImmuneIEDB
Conditions an epitope on SPTLC2 was assayed in.
- melanoma T cell
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.39
- gnomAD pLI
- 0.78
- gnomAD missense Z
- 2.04
- DepMap mean gene effect
- -0.28
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 5% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- adipose tissue development
- ceramide biosynthetic process
- positive regulation of lipophagy
- sphinganine biosynthetic process
- sphingolipid biosynthetic process
- sphingomyelin biosynthetic process
- sphingosine biosynthetic process
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
- Aminotransferase, class-II, pyridoxal-phosphate binding site
- Aminotransferase, class I/classII, large domain
- Pyridoxal phosphate-dependent transferase, major domain
- Pyridoxal phosphate-dependent transferase, small domain
- Pyridoxal phosphate-dependent transferase
- 8-amino-7-oxononanoate synthase class-II
- Aminotransferase class I and II
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of SPTLC2 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads SPTLC2 as an antibody target. Whether an autoantibody or antibody against SPTLC2 could matter depends on whether native SPTLC2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
SPTLC2 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label SPTLC2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...